# Sensus Healthcare, Inc.: Form 10-Q for the period ended Sep 30, 2020

- Company: [Sensus Healthcare, Inc.](/companies/srts.md) (CIK 1494891)
- Form: 10-Q
- Filed: 2020-11-10
- Accepted by EDGAR: Nov 10, 2020, 13:44 ET
- Period: 2020-09-30
- Accession: 0001213900-20-036128
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1494891/000121390020036128/f10q0920_sensushealthcare.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1494891/000121390020036128/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-07-01 to 2020-09-30 | $1.6m | us-gaap:Revenues |
| Revenue | 9 months, 2020-01-01 to 2020-09-30 | $4.5m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2020-07-01 to 2020-09-30 | $947.8k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2020-01-01 to 2020-09-30 | $2.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2020-07-01 to 2020-09-30 | $672.4k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2020-01-01 to 2020-09-30 | $2.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-07-01 to 2020-09-30 | $941.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2020-01-01 to 2020-09-30 | $3.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-07-01 to 2020-09-30 | −$2.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-01-01 to 2020-09-30 | −$8.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-07-01 to 2020-09-30 | $2.6k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2020-01-01 to 2020-09-30 | $17.0k | us-gaap:InterestExpense |
| Income tax | 9 months, 2020-01-01 to 2020-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-07-01 to 2020-09-30 | −$1.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-01-01 to 2020-09-30 | −$7.9m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months, 2020-01-01 to 2020-09-30 | −$73.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-01-01 to 2020-09-30 | $254.9k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-09-30 | $16.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-09-30 | $24.6m | us-gaap:AssetsCurrent |
| Total assets | at 2020-09-30 | $27.7m | us-gaap:Assets |
| Current liabilities | at 2020-09-30 | $4.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-09-30 | $7.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-09-30 | $20.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 18,379 characters.

*You should read the following discussion and analysis in conjunction with the information set forth within the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and with our Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2019 (“Annual Report This discussion includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Our actual results may differ materially from those contained in or implied by any forward-looking statements. Please see the Introductory Note and Item 1A. Risk Factors of our Annual Report, as updated in our Report on Form 10-Q for the quarter ended March 31, 2020, and in our other filings made from time to time with the SEC after the date of this report.*

### Overview

We are a medical device company that is committed to providing highly effective, non-invasive and cost-effective treatments for both oncological and non-oncological skin conditions. We use a proprietary low-energy X-ray technology known as superficial radiation therapy (“SRT”), which is a result of over a decade of dedicated research and development. We have successfully incorporated SRT into our portfolio of treatment devices: the SRT-100TM, SRT-100+TM and SRT-100 VisionTM. In February 2019, we received FDA clearance of Sculptura™, a robotic radiation oncology system that provides targeted intraoperative triple-modulated radiotherapy and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, with a single dose. In August 2020, the Company acquired two mobile aesthetic laser rental companies that are expected to complement and expand the Company’s current offerings.

### Components of our results of operations

We manage our business globally within one reportable segment, which is consistent with how our management reviews our business, prioritizes investment and resource allocation decisions and assesses operating performance.

### Significant Developments

The outbreak of COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts to our employees, operations, and customer demand. We provide medical devices and are considered an “essential business” and have been able to continue to operate. However, the COVID-19 pandemic has significantly impacted our sales and could further impact our operations and the operations of our customers, suppliers and vendors as a result of ongoing quarantines, facility closures, and travel and logistics restrictions. The extent to which the COVID-19 pandemic impacts our business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on our customers, suppliers, and vendors, the remedial actions and stimulus measures adopted by local, state and federal governments, and to what extent normal economic and operating conditions can resume. Even after the COVID-19 pandemic subsides, we may continue to experience adverse impacts to our business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, we cannot reasonably estimate the impact at this time.

### Results of Operations

|  | For the Three Months Ended September 30, 2020 | 2019 | For the Nine Months Ended September 30, 2020 | 2019 |
| --- | ---: | ---: | ---: | ---: |
| **Revenues** | $1,620,163 | $5,840,945 | $4,482,557 | $18,753,839 |
| **Cost of Sales** | 947,786 | 1,997,111 | 2,462,024 | 6,654,835 |
| **Gross Profit** | 672,377 | 3,843,834 | 2,020,533 | 12,099,004 |
| **Operating Expenses** |  |  |  |  |
| Selling and marketing | 1,034,170 | 2,124,146 | 3,986,985 | 6,649,754 |
| General and administrative | 975,876 | 957,184 | 3,209,536 | 2,933,985 |
| Research and development | 941,735 | 1,567,634 | 3,315,245 | 5,467,947 |
| **Total Operating Expenses** | 2,951,781 | 4,648,964 | 10,511,766 | 15,051,686 |
| **Loss From Operations** | (2,279,404) | (805,130) | (8,491,233) | (2,952,682) |
| **Other Income (Expense)** |  |  |  |  |
| Gain on acquisition | 588,011 | — | 588,011 |  |
| Interest income | 1,718 | 74,736 | 66,304 | 213,578 |
| Interest expense | (2,578) | — | (17,023) | — |
| **Other Income (Expense), net** | 587,151 | 74,736 | 637,292 | 213,578 |
| **Net Loss** | $(1,692,253) | $(730,394) | $(7,853,941) | $(2,739,104) |

### Three months ended September 30, 2020 compared to the three months ended September 30, 2019

**Revenue.** Revenue was $1,620,163 for the three months ended September 30, 2020 compared to $5,840,945 for the three months ended September 30, 2019, a decrease of $4,220,782 or 72.3%. The decrease was driven by the lower number of units sold, reflecting the impact of the COVID-19 outbreak, through the third quarter. COVID-19 continued to significantly impact our business in the third quarter of 2020. Whether and to what extent our revenue improves for the fourth quarter of 2020 is largely dependent upon the status of the COVID-19 pandemic and the market’s response to the pandemic.

**Cost of sales**. Cost of sales was $947,786 for the three months ended September 30, 2020 compared to $1,997,111 for the three months ended September 30, 2019, a decrease of $1,049,326, or 52.5%. The decrease in cost of sales was commensurate with the decrease in sales.

**Gross profit.** Gross profit was $672,377 for the three months ended September 30, 2020 compared to $3,843,834 for the three months ended September 30, 2019, a decrease of $3,171,457, or 82.5%. Our overall gross profit percentage was 41.5% in the three months ended September 30, 2020 compared to 65.8% in the corresponding period in 2019. The decrease in gross profit was mostly due to the decrease in units sold as a result of the COVID-19 outbreak while still incurring fixed compensation costs, depreciation and amortization expenses. Gross margin, as a percentage of revenue, might increase for the fourth quarter of 2020 if we experience an increase in sales, but any such increase is largely dependent upon the status of the COVID-19 pandemic and the market’s response to the pandemic.

**Selling and marketing.** Selling and marketing expense was $1,034,170 for the three months ended September 30, 2020 compared to $2,124,146 for the three months September 30, 2019, a decrease of $1,089,976, or 51.3%. The decrease was primarily attributable to cancellations of trade shows due to COVID-19, a decrease in commission expense due to lower sales and reduced spending on marketing activities.

**General and administrative.** General and administrative expense was $975,876 for the three months ended September 30, 2020 compared to $957,184 for the three months ended September 30, 2019 was relatively unchanged.

**Research and development.** Research and development expense was $941,735 for the three months ended September 30, 2020 compared to $1,567,634 for the three months ended September 30, 2019, a decrease of $625,899, or 39.9%. The decrease in research and development spending was primarily attributable to entering into the production phase of the SculpturaTM project.

**Other income (expense).** Other income was $587,151 for the three months ended September 30, 2020 compared to $74,736 for the three months ended September 30, 2019, an increase of $512,415 or 685.6%. The net increase was primarily attributable to a bargain purchase gain recorded as a result of an acquisition (See Note 2, *Acquisitions*, for more information. In addition, we incurred interest expense in connection with our secured credit facility with Silicon Valley Bank and our loan under the Small Business Administration Paycheck Protection Program, and we received interest income from our cash investments. Interest income decreased due to the maturing of our investment in debt securities.

### Nine months ended September 30, 2020 compared to the nine months ended September 30, 2019

**Revenue.** Revenue was $4,482,557 for the nine months ended September 30, 2020 compared to $18,753,839 for the nine months ended September 30, 2019, a decrease of $14,271,282 or 76.1%. Whether, and to what extent, our revenue improves in the fourth quarter of 2020 is largely dependent upon the status of the COVID-19 pandemic and the market’s response to the pandemic.

**Cost of sales**. Cost of sales was $2,462,024 for the nine months ended September 30, 2020 compared to $6,654,835 for the nine months ended September 30, 2019, a decrease of $4,192,811, or 63.0%. The decrease in cost of sales was commensurate with the decrease in sales.

**Gross profit.** Gross profit was $2,020,533 for the nine months ended September 30, 2020 compared to $12,099,004 for the nine months ended September 30, 2019, a decrease of $10,078,471, or 83.3%. Our overall gross profit percentage was 45.1% in the nine months ended September 30, 2020 compared to 64.5% in the corresponding period in 2019. The decrease in gross profit was mostly due to the decrease in units sold as a result of the COVID-19 outbreak while still incurring fixed compensation costs, depreciation and amortization expenses. Gross margin, as a percentage of revenue, might increase for the fourth quarter of 2020 if we experience an increase in sales, but any such increase is largely dependent upon the status of the COVID-19 pandemic and the market’s response to the pandemic.

**Selling and marketing.** Selling and marketing expense was $3,986,985 for the nine months ended September 30, 2020 compared to $6,649,754 for the nine months ended September 30, 2019, a decrease of $2,662,769, or 40.0%. The decrease was primarily attributable to a decrease in tradeshows expense due to cancellations related to COVID-19, a decrease in commission expense due to lower sales and reduced spending on marketing activities.

**General and administrative.** General and administrative expense was $3,209,536 for the nine months ended September 30, 2020 compared to $2,933,985 for the nine months ended September 30, 2019, an increase of $275,551, or 9.4%. The net increase in general and administrative expense was primarily due to an increase in bad debt, one-time severance costs, and insurance expense offset by reductions in travel and headcount.

**Research and development.** Research and development expense was $3,315,245 for the nine months ended September 30, 2020 compared to $5,467,947 for the nine months ended September 30, 2019, a decrease of $2,152,702, or 39.4%. The decrease in research and development spending was primarily attributable to entering into the production phase of the SculpturaTM project.

**Other income (expense).** Other income was $637,292 for the nine months ended September 30, 2020 compared to $213,578 for the nine months ended September 30, 2019, an increase of $423,714 or 198.4%. The net increase was primarily attributable to a bargain purchase gain recorded as a result of an acquisition (See Note 2, *Acquisitions*, for more information. We incurred interest expense in connection with our secured credit facility with Silicon Valley Bank and our loan under the Small Business Administration Paycheck Protection Program, and we received interest income from our cash investments. Interest income decreased due to the maturing of our investment in debt securities.

### Financial Condition

Our cash, cash equivalent and investment balance increased to $16,127,085 at September 30, 2020 from $15,489,695 at December 31, 2019, primarily due to cash provided in financing activities of $966,014.

There were no borrowings under the revolving line of credit at September 30, 2020 or December 31, 2019.

In light of the COVID-19 pandemic, we have taken proactive steps to manage our costs and bolster our liquidity. We increased our borrowing availability as a precautionary measure to preserve financial flexibility due to the current uncertainty in the global markets resulting from the COVID-19 pandemic. In addition, we received a loan under the Small Business Administration Paycheck Protection Program enabled by the CARES Act of 2020 to be used for employee compensation and facilities costs.

### Liquidity and Capital Resources

### Overview

Our liquidity position and capital requirements may be impacted by a number of factors, including the following:

- our ability to generate and increase revenue;
- fluctuations in gross margins, operating expenses and net results;
- the impact of COVID-19; and
- fluctuations in working capital.

Our primary short-term capital needs, which are subject to change, include expenditures related to:

- expansion of our sales, marketing and distribution activities; and
- expansion of our research and development activities.

We regularly evaluate our cash requirements for current operations, commitments, capital requirements and business development transactions, and we may elect to raise additional funds for these purposes in the future.

### Cash flows

The following table provides a summary of our cash flows for the periods indicated:

*(unaudited)*

| Net Cash Provided by (Used In): | For the Nine Months Ended September 30, 2020 | 2019 |
| --- | ---: | ---: |
| Operating Activities | $(73,761) | $(2,566,572) |
| Investing Activities | 7,134,544 | (5,632,621) |
| Financing Activities | 966,014 | 2,620,484 |
| Total | $8,026,797 | $(5,578,709) |

### Cash flows from operating activities

Net cash used in operating activities was $73,761 for the nine months ended September 30, 2020, consisting of a net loss of $7,853,941 partially offset by a decrease in net operating assets of $7,369,649, and by non-cash charges of $410,531. The decrease in net operating assets was primarily due to a decrease in accounts receivable, partially offset by an increase in inventories, accounts payable and accrued expenses, warranties and deferred revenue. Non-cash charges consisted of gain a on bargain purchase (See Note 2, *Acquisitions*, for more information, allowance for bad debt, stock compensation expense, depreciation and amortization, and a warranty provision. Net cash used in operating activities was $2,566,572 for the nine months ended September 30, 2019, primarily reflecting the operating loss and the increase in accounts receivable and accounts payable and accrued expenses partially offset by an increase in deferred revenue.

### Cash flows from investing activities

Net cash provided by investing activities was $7,134,544, mostly due to matured investments of $7,389,407 during the nine months ended September 30, 2020. Net cash used in investing activities was $5,632,621 for the nine months ended September 30, 2019 due to the purchase of debt securities held-to-maturity of $8,390,137, partially offset by $3,300,000 for investments matured.

### Cash flows from financing activities

Net cash provided by financing activities was $966,014 during the nine months ended September 30, 2020 mostly from a loan of $1,022,785 under the Small Business Administration Paycheck Protection Program. Net cash provided by financing activities was $2,620,484 during the nine months ended September 30, 2019, mainly from the exercise of 405,813 warrants.

### Indebtedness

Please see Note 5 to the financial statements.

### Off-Balance Sheet Arrangements

We did not have, during the periods presented, and do not currently have, any off-balance sheet arrangements.

### Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S., or GAAP. We have identified certain accounting policies as critical to understanding our financial condition and results of our operations. For a detailed discussion on the application of these and other accounting policies, see the notes to our financial statements in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2019.

### JOBS Act

We qualify as an “emerging growth company” pursuant to the provisions of the JOBS Act. For as long as we are an “emerging growth company,” we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including, but not limited to, the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, reduced disclosure obligations relating to the presentation of financial statements in Management’s Discussion and Analysis of Financial Condition and Results of Operations, exemptions from the requirements of holding advisory “say-on-pay” votes on executive compensation, and shareholder advisory votes on golden parachute compensation. We have availed ourselves of the reduced reporting obligations in this Quarterly Report on Form 10-Q, and expect to continue to avail ourselves of the reduced reporting obligations available to emerging growth companies in future filings.

In addition, an emerging growth company can delay its adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we have chosen to “opt out” of such extended transition period, and as a result, we plan to comply with any new or revised accounting standards on the relevant dates on which non-emerging growth companies must adopt such standards. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.

## Controls and procedures

As filed, 927 characters.

### Evaluation of Disclosure Control and Procedures

As of September 30, 2020, the end of the period covered by this Form 10-Q, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer each concluded that, as of September 30, 2020, the end of the period covered by this Form 10-Q, we maintained effective disclosure controls and procedures.

### Changes in Internal Control over Financial Reporting

There have been no significant changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 577 characters.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K, as updated in our subsequent quarterly reports. The risks described in our Annual Report on Form 10-K and our subsequent quarterly reports are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results.

Filed Nov 10, 2020.
Source: SEC EDGAR, the filing index for accession 0001213900-20-036128. Last ingested by Listed: Nov 14, 2026, 13:10 ET. No prices; not investment advice.
